LLY

1,139.44

-1.38%↓

JNJ

235.89

+2.07%↑

ABBV

224.86

+1.61%↑

UNH

409.98

+1.81%↑

MRK

119.57

+0.27%↑

LLY

1,139.44

-1.38%↓

JNJ

235.89

+2.07%↑

ABBV

224.86

+1.61%↑

UNH

409.98

+1.81%↑

MRK

119.57

+0.27%↑

LLY

1,139.44

-1.38%↓

JNJ

235.89

+2.07%↑

ABBV

224.86

+1.61%↑

UNH

409.98

+1.81%↑

MRK

119.57

+0.27%↑

LLY

1,139.44

-1.38%↓

JNJ

235.89

+2.07%↑

ABBV

224.86

+1.61%↑

UNH

409.98

+1.81%↑

MRK

119.57

+0.27%↑

LLY

1,139.44

-1.38%↓

JNJ

235.89

+2.07%↑

ABBV

224.86

+1.61%↑

UNH

409.98

+1.81%↑

MRK

119.57

+0.27%↑

Home・Akciju saraksts・Charles River Laboratories International Inc

Charles River Laboratories International Inc

Atvērts

SektorsVeselības aprūpe

186.94 1.11

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

184.18

Max

192.86

Galvenie mērījumi
By Trading Economics
Ienākumi	262M -15M
Pārdošana	1.6M 996M
EPS	-0.3
Peļņas marža	-1.486
Darbinieki	18,300
EBITDA	-11M 187M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+11.78% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 5. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	267M 8.8B
Iepriekšējā atvēršanas cena	185.83
Iepriekšējā slēgšanas cena	186.94

Ziņu noskaņojums

By Acuity

50%

161 / 344 Rangs Healthcare

Charles River Laboratories International Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 8. jūn. 22:20 UTC

Iegādes, apvienošanās, pārņemšana

Salesforce to Buy m3ter in Nod Toward AI-Native Business Models

2026. g. 8. jūn. 15:41 UTC

Galvenie tirgus virzītāji

American Battery Shares Jump on Energy Department Victory

2026. g. 8. jūn. 23:46 UTC

Tirgus saruna

Nikkei May Rebound After Monday's Selloff -- Market Talk

2026. g. 8. jūn. 23:37 UTC

Tirgus saruna

Oil Edges Higher Amid Ongoing Supply Disruption Concerns -- Market Talk

2026. g. 8. jūn. 23:25 UTC

Tirgus saruna

Should Australia Consider State-Linked Commodities Export Desk? -- Market Talk

2026. g. 8. jūn. 23:25 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 8. jūn. 21:57 UTC

Iegādes, apvienošanās, pārņemšana

Salesforce Expects to Close Deal in 2Q of Fiscal 2027

2026. g. 8. jūn. 21:56 UTC

Iegādes, apvienošanās, pārņemšana

Salesforce Agrees to Buy m3ter

2026. g. 8. jūn. 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 8. jūn. 19:22 UTC

Tirgus saruna

Oil Settles Higher as Israel-Iran Exchanges Raise Tension -- Market Talk

2026. g. 8. jūn. 19:01 UTC

Tirgus saruna

U.S. Natural Gas Futures Pull Back on Weather Outlook -- Market Talk

2026. g. 8. jūn. 18:52 UTC

Tirgus saruna

Global Energy Roundup: Market Talk

2026. g. 8. jūn. 18:52 UTC

Tirgus saruna

CAD Needs Trade Deal to Trigger Sustained Rally -- Market Talk

2026. g. 8. jūn. 18:17 UTC

Tirgus saruna

Oil Pulls Back Further As Iran, Israel Put Strikes on Hold -- Market Talk

2026. g. 8. jūn. 17:32 UTC

Tirgus saruna

Bank of Canada Should Incorporate Unemployment Rate Into Its Forecast -- Market Talk

2026. g. 8. jūn. 17:29 UTC

Tirgus saruna

Crypto Market Still Stays in 'Extreme Fear' Amid Rebound -- Market Talk

2026. g. 8. jūn. 17:29 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 8. jūn. 16:55 UTC

Iegādes, apvienošanās, pārņemšana

Monte dei Paschi: Mediobanca Integration Proceeding According to Plan

2026. g. 8. jūn. 16:54 UTC

Iegādes, apvienošanās, pārņemšana

Monte dei Paschi to Review Proposals From Banco BPM, Intesa Sanpaolo

2026. g. 8. jūn. 16:40 UTC

Tirgus saruna

Cryptocurrencies Rise After Iran and Israel Halt Exchanges of Fire -- Market Talk

2026. g. 8. jūn. 16:31 UTC

Tirgus saruna

No Recession in Canada, Scotiabank's CEO Says -- Market Talk

2026. g. 8. jūn. 16:27 UTC

Tirgus saruna

Mexican Inflation Seen Easing in May -- Market Talk

2026. g. 8. jūn. 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 8. jūn. 16:03 UTC

Iegādes, apvienošanās, pārņemšana

Orange Bought Stake From Lorca

2026. g. 8. jūn. 16:01 UTC

Iegādes, apvienošanās, pārņemšana

Orange Completes Acquisition of Remaining 50% Stake in MasOrange

2026. g. 8. jūn. 16:01 UTC

Iegādes, apvienošanās, pārņemšana

Orange Acquires 100% Ownership of MasOrange

2026. g. 8. jūn. 15:58 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 8. jūn. 15:58 UTC

Tirgus saruna

Gold Trims Losses After Israel, Iran Halt Exchanges of Fire -- Market Talk

2026. g. 8. jūn. 15:55 UTC

Tirgus saruna

Markets Price Small Chance USMCA Will Be Dismantled -- Market Talk

2026. g. 8. jūn. 15:41 UTC

Tirgus saruna

Gold Falls Below 200-Day Moving Average -- Market Talk

Salīdzinājums

Cenas izmaiņa

Charles River Laboratories International Inc Prognoze

Cenas mērķis

By TipRanks

11.78% augšup

Prognoze 12 mēnešiem

Vidējais 208.4 USD 11.78%

Augstākais 235 USD

Zemākais 160 USD

Pamatojoties uz 12 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Charles River Laboratories International Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

12 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 12 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Charles River Laboratories International Inc — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

161 / 344 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.